ArticleOncology research2026
Machine Learning (ML) and Molecular Dynamics-Driven Optimization of VEGFR2 Ligands against Hepatocellular Carcinoma.
Article in Oncology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Vascular endothelial growth factor receptor 2 (VEGFR2) is a critical therapeutic target in hepatocellular carcinoma (HCC) due to its role in angiogenesis and tumor progression. While several inhibitors are currently used, clinical utility is often limited by resistance and adverse effects, necessitating the discovery of novel therapeutic agents. The aim of this study was to identify and characterize novel, highly effective VEGFR2 inhibitors using an integrated computational pipeline to advance the development of new HCC treatments. Methods: A comprehensive dataset from the ChEMBL database was curated and standardized for Quantitative Structure-Activity Relationship (QSAR) modeling. A binary classification framework was employed, where a Light Gradient Boosting Machine (LGBM) model demonstrated superior predictive performance. Two lead compounds and a reference were selected for in-depth molecular modeling. Their binding poses were predicted via molecular docking and subsequently subjected to 200 ns Molecular Dynamics (MD) simulations to assess stability and conformational dynamics. Thermodynamic binding affinities were calculated using the Molecular Mechanics Poisson-Boltzmann Surface Area (MMPBSA) method. Results: The LGBM model achieved high accuracy and a robust Matthews Correlation Coefficient (MCC) on an independent test set. MD analysis, including Root Mean Square Deviation (RMSD) and Radius of Gyration (Rg), confirmed stable binding throughout the 200 ns trajectory. MMPBSA calculations validated the binding affinities, identifying van der Waals and electrostatic interactions as the primary driving forces for complex stability. Conclusion: This study successfully bridges machine learning with advanced molecular simulations, offering a validated workflow for the rational design and optimization of novel small-molecule VEGFR2 inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.